CASI CASI Pharmaceuticals: יחס שווי שוק לערך בספרים

CASI Pharmaceuticals minimizes R&D risks by introducing Western oncology drugs into China through licensing agreements. Business growth relies on EVOMELA sales, the development of CID-103, and Asian partnerships, with the metric standing at -0.13. This daily price chart visualizes the stock price action of this drug developer. The brand's high authority in hematology and the trust of medical professionals serve as a solid foundation for the company's further scaling.

CASI Pharmaceuticals is developing a cross-border business to introduce Western hematological drugs in China and the US. The value of these assets is compared with the market price of shares to calculate the ratio. This metric determines the investor premium over net tangible assets, separating fundamental value from speculative hype. An increase in the market-to-book ratio signals growing confidence in future earnings. Analyzing this chart helps avoid capital freeze during the revaluation of the issuer.